TradingKey - On October 30, AstraZeneca (AZN) shares rose more than 5% in pre-market trading. The company's third-quarter revenue and earnings both exceeded market expectations, while it reaffirmed its full-year guidance and announced a restructuring plan expected to unlock $1.5 billion in annual benefits, bolstering investor confidence in its medium- to long-term growth prospects.

TradingKeyFri, Oct 30

AstraZeneca, Bristol Myers Squibb in Merger Talks to Create Nearly $400 Billion Pharma Giant

TradingKey - British pharmaceutical giant AstraZeneca (AZN) is in talks with its U.S. peer Bristol Myers Squibb (BMY) regarding a potential merger. If a deal is reached, the combined market capitalization of the two entities would approach $400 billion, potentially creating one of the world's largest pharmaceutical groups.

TradingKeyMon, Aug 3

AstraZeneca Cardiomyopathy Drug Wainua Fails to Meet Late-Stage Clinical Trial Goal as Shares Plunge Over 8% Pre-Market.

TradingKey - On Thursday local time, AstraZeneca (AZN) announced the failure of a key late-stage clinical trial for its investigational drug Wainua, triggering an intraday plunge of up to 8% to $173 in US pre-market trading.

TradingKeyThu, Jul 9

George Soros Q2 2025 13F Report: Tactical Bets and Market Mastery Unveiled

TradingKey - George Soros, the iconic financier and chairman of Soros Fund Management, remains a defining figure in global investing. Widely recognized for his theory of market reflexivity, which contends that investor biases and market fundamentals form feedback loops influencing asset prices

TradingKeyAug 15, 2025

George Soros’s Playbook in 2025: Opportunistic, Nimble, and Undeniably Contrarian

TradingKey - When ordinary investors hear George Soros's name, it evokes that hedge fund legend who “broke the Bank of England,” but today Soros Fund Management trades with a system that is far more complicated than speculating in currencies.

TradingKeyJul 4, 2025